Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212290 · ClinicalTrials.gov registry record · Phase 4
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT00212290: Completed Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00212290 is a Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 140 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00212290, a Phase 4 study of Type 2 Diabetes Mellitus and Insulin Resistance, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
Conditions Studied
Interventions
- DRUG placebo
- DRUG pioglitazone
- DRUG nateglinide
Study Locations (2)
Washington
- VA Puget Sound Health Care System (Seattle Campus) - Seattle
- VA Puget Sound Health Care System (American Lake Campus) - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
What the finished NCT00212290 record still lists
NCT00212290 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00212290 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00212290 about?
NCT00212290 is a clinical study titled "Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes". The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
What is the current status of trial NCT00212290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2002-11. Estimated completion is 2006-12.
What conditions does trial NCT00212290 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Insulin Resistance.
What interventions are being tested in trial NCT00212290?
The interventions under investigation include: placebo (DRUG), pioglitazone (DRUG), nateglinide (DRUG).
Who is sponsoring clinical trial NCT00212290?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00212290 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00212290's enrollment target sits among peer trials
140 47th of 130 higher than 84 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
COMPLETED · Phase 4
-
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia